AstraZeneca ' s Drug Fasenra Flops in COPD Trial AstraZeneca ' s Drug Fasenra Flops in COPD Trial

AstraZeneca ' s said its first respiratory biologic medicine Fasenra (benralizumab) failed to meet its target in a clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news